Biocon · NSE: BIOCON · BSE: 532523

Q4 FY20 results · Jan–Mar 2020

Biocon reported revenue from operations of ₹1,581.00 crore (up 3.4% from Q4 FY19) and net profit of ₹159.10 crore (down 34.6% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	1,581.00	1,528.80	+3.4%	1,748.10	−9.6%
Other income	63.10	28.20	+123.8%	35.80	+76.3%
Total income	1,644.10	1,557.00	+5.6%	1,783.90	−7.8%
Profit before share of associates & JVs and tax	212.50	295.50	−28.1%	318.30	−33.2%
Share of profit/(loss) of associates & JVs	(8.40)	(11.20)		(3.20)
Net profit for the period	159.10	243.40	−34.6%	230.30	−30.9%
Attributable to shareholders of the company	123.40	213.70	−42.3%	202.80	−39.2%
EPS, basic (₹)	1.04	3.61	not comparable	1.71	−39.2%
Net margin (%)	10.1	15.9		13.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	482.40	763.90	−36.9%	501.30	−3.8%
Other income	67.20	13.90	+383.5%	51.20	+31.2%
Total income	549.60	777.80	−29.3%	552.50	−0.5%
Profit before tax	108.50	74.30	+46.0%	157.80	−31.2%
Net profit for the period	102.20	70.50	+45.0%	120.70	−15.3%
EPS, basic (₹)	0.86	1.19	not comparable	1.02	−15.7%
Net margin (%)	21.2	9.2		24.1

Consolidated

Filed with BSE: 15 May 2020, 18:56 IST
Board meeting: 14 May 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 15 May 2020, 18:56 IST
Board meeting: 14 May 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE